Our Team

Erica Pascal

Founder and CEO

Dr. Erica Pascal began her career in science studying the control of gene expression of mammals, plants and viruses.  She received her B.S. degree in biology from the Massachusetts Institute of Technology.   She obtained a Ph.D. in biochemistry and molecular biology from the University of California at Berkeley where she worked in the laboratory of Dr. Robert Tjian.  Dr. Pascal did her post-doctoral work at the University of Illinois and then worked for 8 years in research and management in the biotech industry.  She received her J.D. from California Western School of law, graduating summa cum laude.

Prior to the creation of Ingensity™ IP, Dr. Pascal was a partner at a major global law firm.  Her practice focused on strategic intellectual property issues for life sciences companies, including pharmaceuticals, biologics, diagnostic technologies and medical devices.  Her experience includes strategic advice for life sciences companies, IP due diligence, litigation risk assessments, pre-trial and trial work. In addition to patent-related matters, Dr. Pascal has worked with clients on issues of false advertising and trade secret protection.

Dr. Pascal is registered to practice as a patent attorney with the USPTO.  She is admitted to practice in California and admitted to the Southern and Central Districts of California as well as the Federal Circuit.  Prior to her work in patent litigation and strategic counseling, Dr. Pascal worked in patent prosecution including drafting and prosecuting patents in the US and worldwide for life science clients.

Dr. Pascal is a frequent author of articles and posts about the life sciences industry and the intersection of business and law.  Find her articles here.  Her interest in the start-up world grew out of her work in the biotech industry, including entering and winning the Duke Startup Challenge in 2001.

Key Experience

Exemplary Current and Prior Matters

IP Strategy Counseling

  • Therapeutics
  • Food & nutrition
  • Bio-materials
  • Molecular diagnostics
  • Surgical devices
  • Digital health (B2C and B2B models for healthcare and well-being)

Life Science-Related Diligence

  • Stem-cell therapy
  • Oncology small molecule drug
  • Orphan drug portfolio
  • Laparoscopic medical device products
  • Hemodialysis product
  • Nucleic acid diagnostics assays

Life Science-Related Litigations

  • Pharmaceuticals including small molecule and antibody drugs
  • Diagnostic assays and reagents
  • Medical devices including insufflators, trocars, energy-based surgical instruments, and infusion pumps

Summary of Background


  • B.S. MIT (Biology)
  • Ph.D. UC Berkeley (Biochemistry/Molecular Biology)
  • Post-doctoral Fellow U. Illinois (Plant Virology)
  • Research Director (Ciba/Novartis)


  • Previously partner at global law firm (DLA Piper)
  • Registered patent attorney (USPTO)
  • Clerked for the Honorable Rudi M. Brewster (U.S. District Court, Southern District, California)


  • Biotech Portfolio Management (Novartis/Syngenta)
  • Winner of the Duke Start-up Challenge 2001